Chessick CA, Allen MH, Thase M, et al. (2006). Chessick, Cheryl A. ur. „Azapirones for generalized anxiety disorder”. Cochrane Database of Systematic Reviews (Online)3: CD006115. DOI:10.1002/14651858.CD006115. PMID16856115.
Appelberg BG, Syvälahti EK, Koskinen TE, Mehtonen OP, Muhonen TT, Naukkarinen HH (June 2001). „Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study”. The Journal of Clinical Psychiatry62 (6): 448–52. DOI:10.4088/JCP.v62n0608. PMID11465522.
Chessick CA, Allen MH, Thase M, et al. (2006). Chessick, Cheryl A. ur. „Azapirones for generalized anxiety disorder”. Cochrane Database of Systematic Reviews (Online)3: CD006115. DOI:10.1002/14651858.CD006115. PMID16856115.
Bouwer C, Stein DJ (April 1997). „Buspirone is an effective augmenting agent of serotonin selective re-uptake inhibitors in severe treatment-refractory depression”. South African Medical Journal87 (4 Suppl): 534–7, 540. PMID9180827.
Appelberg BG, Syvälahti EK, Koskinen TE, Mehtonen OP, Muhonen TT, Naukkarinen HH (June 2001). „Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study”. The Journal of Clinical Psychiatry62 (6): 448–52. DOI:10.4088/JCP.v62n0608. PMID11465522.